clinical trial results

Altimmune, Inc. (ALT) on Friday reported positive topline results from the IMPACT Phase 2b trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) at 48 weeks. Topline data showed that pemvidutide achieved statistically significant improvements across treatment...

Ipsen (IPSEY) said on Friday that its pivotal Phase II FALKON study evaluating fidrisertib in patients with fibrodysplasia ossificans progressiva (FOP) failed to meet its primary endpoint, prompting the company to close the trial. The primary endpoint was the reduction of new heterotopic ossification,...

Eli Lilly and Company (LLY), Thursday announced positive topline results from the Phase 3 ATTAIN-MAINTAIN trial, which evaluated orforglipron for weight maintenance in participants who were earlier treated with Wegovy or Zepbound. During the randomized, double-blind trial, the company evaluated efficacy...

4D Molecular Therapeutics Inc. (FDMT) on Wednesday reported positive interim results from its Phase 1 AEROW study evaluating 4D-710, the company's gene therapy candidate for the treatment of cystic fibrosis lung disease. The study enrolled patients with cystic fibrosis who were ineligible for or intolerant...

Galderma Group AG (GDERF, GALD.SW), a dermatology company, on Tuesday released new clinical findings confirming that Nemluvio showed significant relief of itch and sleep disturbances within 48 hours in patients with atopic dermatitis and prurigo nodularis. The findings from post-hoc analyses of the...

Actuate Therapeutics, Inc. (ACTU) on Monday reported positive results from a Phase II study evaluating elraglusib in combination with carboplatin or cisplatin in patients with advanced metastatic salivary gland cancers, including adenoid cystic carcinoma (ACC) and other subtypes. The study enrolled...

Palvella Therapeutics, Inc. (PVLA) on Monday announced positive topline results from its Phase 2 TOIVA study of QTORIN 3.9% rapamycin anhydrous gel for the treatment of cutaneous venous malformations. Cutaneous venous malformations are congenital, chronic, progressive lesions that persist throughout...

AC Immune SA (ACIU), Thursday announced positive interim safety and efficacy results from the Phase 2 VacSYn trial of anti-alpha-synuclein active immunotherapy ACI-7104.056 in early Parkinson's disease. The findings noted that ACI-7104.056 induced a robust antibody response against the immunizing...

Rezolute, Inc. (RZLT), a rare disease company, announced Thursday topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism (HI). The study did not meet its primary endpoint, which assessed change in the average weekly hypoglycemia events by self-monitored...

Corbus Pharmaceuticals Holdings Inc. (CRBP) on Thursday reported positive results from a Phase 1a study evaluating CRB-913 for chronic obesity management. The news sent the company's shares up more than 14% in pre-market trading.

Eli Lilly and Co. (LLY) announced Thursday positive topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating the safety and efficacy of the two highest investigational doses of retatrutide, a first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, in adults with obesity or...

Roche Holding AG (RHHBY) on Wednesday reported positive results from the phase III lidERA study of giredestrant in oestrogen receptor (ER)-positive early-stage breast cancer. The adjuvant endocrine therapy reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care...

Senti Biosciences, Inc. (SNTI), Tuesday announced new data from its ongoing trial of SENTI-202, evaluating the safety, efficacy, and pharmacodynamics of the treatment, when administered after Fludarabine/lymphodepletion in patients with relapsed or refractory Acute Myeloid Leukemia. The findings revealed...

BioNTech SE (BNTX) and Bristol-Myers Squibb Company (BMY), Tuesday announced the first interim data from a global randomized Phase 2 trial, evaluating pumitamig in patients with locally advanced/metastatic triple-negative breast cancer. The trial evaluated pumitamig in two dose levels and in combination...

Eli Lilly and Co. (LLY) announced Tuesday results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, versus bendamustine plus rituximab (BR), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic...